FDA
-
-
-
-
-
-
-
Tyra Biosciences Strengthens Leadership Team with Appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer
-
-
-
-
-
-
-
Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights
-
-
-
-
-
-
-
Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights
-
-
-
-
-
-
-
Tyra Biosciences Reports Second Quarter 2024 Financial Results and Highlights
-
-
-
-
-
-
-
Tyra Biosciences (TYRA) Receives FDA Rare Pediatric Disease Designation for TYRA-300
-
-
-
-
-
-
-
Tyra Biosciences Reports First Quarter 2023 Financial Results and Highlights
-
-
-
-
-
-
-
Tyra Biosciences to Present Preclinical Data on TYRA-300, an FGFR3-selective Inhibitor, at ESMO 2022 Congress
-
323,580 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

